The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Ipilimumab + nivolumab in people with rare variant renal cell carcinoma refractory to nivolumab alone: Part 2 of UNISON (ANZUP 1602) nivolumab then ipilimumab + nivolumab in advanced non-clear cell renal cell carcinoma.
 
Craig Gedye
Consulting or Advisory Role - Abbvie (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Merck Sharp & Dohme (Inst); Novotech; Pfizer (Inst)
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst)
Travel, Accommodations, Expenses - Astellas Pharma (Inst); Astellas Pharma (Inst); Merck Sharp & Dohme (Inst)
 
David William Pook
Honoraria - Astellas Pharma; Ipsen; Novartis
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb; Merck Sharp & Dohme; Merck Sharp & Dohme (Inst); Pfizer; Pfizer (Inst)
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche (Inst); SymVivo (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Bristol-Myers Squibb; Pfizer
 
Laurence Eliot Miles Krieger
Honoraria - Astellas Pharma; Ferring; Ipsen; Janssen-Cilag; Janssen-Cilag; MSD Oncology; Pfizer; Roche
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Clovis Oncology; Ferring; Ipsen; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Sanofi
Speakers' Bureau - Abbvie; Janssen; Janssen-Cilag; Merck Sharp & Dohme; Roche
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Janssen-Cilag (Inst); Roche (Inst)
Expert Testimony - Astellas Pharma; Ipsen; Novartis
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Bayer; Ipsen; Ipsen; Janssen; Janssen-Cilag; MSD Oncology; Novartis; Pfizer
 
Carole A. Harris
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Merck; Pfizer
 
Jeffrey C. Goh
Stock and Other Ownership Interests - Immutep
Honoraria - Ipsen
Consulting or Advisory Role - AstraZeneca; Tesaro
Speakers' Bureau - AstraZeneca; Ipsen; Janssen; Mundipharma; Novartis
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca
 
Ganessan Kichenadasse
No Relationships to Disclose
 
Howard Gurney
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Ipsen; Janssen-Cilag; Merck Serono; Merck Sharp & Dohme; Pfizer; Roche
Speakers' Bureau - Merck Serono
Travel, Accommodations, Expenses - AstraZeneca
 
Craig Underhill
Consulting or Advisory Role - Merck Serono
Research Funding - Abbvie (Inst); Akeso Biopharma (Inst); Arcus Biosciences (Inst); AtriCure (Inst); BeyondSpring Pharmaceuticals (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Deciphera (Inst); novotech (Inst)
 
Francis Parnis
Consulting or Advisory Role - Ipsen; Janssen Oncology; Merck Serono
 
Anthony M. Joshua
Consulting or Advisory Role - AstraZeneca (Inst); Ipsen (Inst); IQvia (Inst); Janssen Oncology (Inst); Neoleukin Therapeutics (Inst); Novartis (Inst); Noxopharm (Inst); Pfizer (Inst); Sanofi (Inst)
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Janssen Oncology (Inst); Lilly (Inst); Lilly (Inst); Macrogenics (Inst); Mayne Pharma (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Tom Ferguson
Research Funding - AstraZeneca (Inst); Janssen (Inst); MSD (Inst)
Travel, Accommodations, Expenses - BMS; MSD; Roche
 
Felicia Roncolato
No Relationships to Disclose
 
Michelle L. Harrison
Stock and Other Ownership Interests - CSL Limited (I)
 
Stephen Begbie
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Janssen Oncology; MSD Oncology; Noxopharm; Roche
Research Funding - Astellas Medivation (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Merck (Inst); Merck Serono (Inst); Pfizer/EMD Serono (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Astellas Pharma
 
Michelle Frances Morris
Travel, Accommodations, Expenses - Amgen
 
Elizabeth J. Hovey
Consulting or Advisory Role - Amgen; Janssen Oncology
Travel, Accommodations, Expenses - Amgen
 
Mathew George
No Relationships to Disclose
 
Prashanth Prithviraj
No Relationships to Disclose
 
Emma Link
Patents, Royalties, Other Intellectual Property - Emma is an innovator: the discovery of her DPhil has been the subject of patent applications in the USA, UK, Europe, China, and Japan. The US rights to the patent were granted to Boston Heart Diagnostics which optimised the test on their technology platfo
 
Ian D. Davis
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Ipsen (Inst); Janssen Oncology (Inst); Medivation (Inst); Movember Foundation (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - International Patent Application No: PCT /US2004/032147 (NY-ESO-1) through Ludwig Institute for Cancer Research.